|
1
|
Wang E, Karedan T and Perez CA: New
insights in the treatment of radioiodine refractory differentiated
thyroid carcinomas: to lenvatinib and beyond. Anticancer Drugs.
26:689–697. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y and Gao Z: Clinical application
and progress of PET/CT in differentiated thyroid carcinoma with
positive TG and negative 131I scanning. Chin Med Device
Inf. 17:8–12. 2011.(In Chinese).
|
|
3
|
Bertagna F, Bosio G, Biasiotto G, Rodella
C, Puta E, Gabanelli S, Lucchini S, Merli G, Savelli G, Giubbini R,
et al: F-18 FDG-PET/CT evaluation of patients with differentiated
thyroid cancer with negative I-131 total body scan and high
thyroglobulin level. Clin Nucl Med. 34:756–761. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laurens ST and Oyen WJG: Value of
fluorodeoxyglucose pet/computed tomography patient management and
outcomes in thyroid cancer. Pet Clinics. 10:265–278. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krajewska J and Jarzab B: Novel therapies
for thyroid cancer. Expert Opin Pharmacother. 15:2641–2652. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim TY, Kim WG, Kim WB and Shong YK:
Current status and future perspectives in differentiated thyroid
cancer. Endocrinol Metab (Seoul). 29:217–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lauri CI, Di Traglia S, Galli F,
Pizzichini P and Signore A: Current status of PET imaging of
differentiated thyroid cancer with second generation
radiopharmaceuticals. Q J Nucl Med Mol Imaging. 59:105–115.
2015.PubMed/NCBI
|
|
8
|
Tiedje VI, Schmid KW, Weber F, Bockisch A
and Führer D: Differentiated thyroid cancer. Internist (Berl).
56:153–166; quiz 167–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim SJ, Lee TH, Kim IJ and Kim YK:
Clinical implication of F-18 FDG PET/CT for differentiated thyroid
cancer in patients with negative diagnostic iodine-123 scan and
elevated thyroglobulin. Eur J Radiol. 70:17–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma C, Xie J, Lou Y, Gao Y, Zuo S and Wang
X: The role of TSH for 18F-FDG-PET in the diagnosis of recurrence
and metastases of differentiated thyroid carcinoma with elevated
thyroglobulin and negative scan: A meta-analysis. Eur J Endocrinol.
163:177–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi
H, Sasaki M, Hatakenaka M and Honda H: Detection of residual lymph
node metastases in high-risk papillary thyroid cancer patients
receiving adjuvant I-131 therapy: The usefulness of F-18 FDG
PET/CT. Clin Nucl Med. 35:6–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Panareo S, Rossi R, Cittanti C, Giganti M,
Prandini N, Franceschetti P, De Biasi V, Lunardon S and Feggi L:
Recombinant thyrotropin stimulation improves 18F-FDG PET/CT
sensitivity in patients with recurrent differentiated thyroid
cancer. J Nucl Med. 52(Suppl 1): 13082011.PubMed/NCBI
|
|
13
|
Leboulleux S, Schroeder PR, Busaidy NL,
Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL,
Sherman SI, et al: Assessment of the incremental value of
recombinant thyrotropin stimulation before
2-[18F]-Fluoro-2-deoxy-D-glucose positron emission
tomography/computed tomography imaging to localize residual
differentiated thyroid cancer. J Clin Endocrinol Metab.
94:1310–1316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vera P, Kuhn-Lansoy C, Edet-Sanson A,
Hapdey S, Modzelewski R, Hitzel A, d'Anjou J and Basuyau JP: Does
recombinant human thyrotropin-stimulated positron emission
tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of
recurrence of well-differentiated thyroid carcinoma in patients
with low serum thyroglobulin? Thyroid. 20:15–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hevrouet T, Devillers A, Cuggia M, Bernard
AM, Le Jeune F, Le Dortz L, Herry JY and Garin E: Influence of
rhTSH on 18 FDG uptake in a population of 42 patients with
suspected recurrence of differentiated thyroid carcinoma. Med Nucl
(Paris). 33:321–330. 2009.(In French).
|
|
16
|
Volante M, Collini P, Nikiforov YE,
Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M,
Sobrinho-Simoes M, et al: Poorly differentiated thyroid carcinoma:
The Turin proposal for the use of uniform diagnostic criteria and
an algorithmic diagnostic approach. Am J Surg Pathol. 31:1256–1264.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stokkel MP, Duchateau CS and Dragoiescu C:
The value of FDG-PET in the follow-up of differentiated thyroid
cancer: a review of the literature. Q J Nucl Med Mol Imaging.
50:78–87. 2006.PubMed/NCBI
|
|
18
|
Yamaga LY, Cunha ML, Wagner J, Thom AF,
Daniel MM and Funari MB: Diagnostic value of positron emission
tomography/computed tomography with fluorine-18 fluordeoxyglucose
in patients with differentiated thyroid gland carcinoma, high
thyroglobulin serum levels and negative iodine whole body scan. Arq
Bras Endocrinol Metabol. 51:581–586. 2007.(In Portuguese).
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rivera M, Ghossein RA, Schoder H, Gomez D,
Larson SM and Tuttle RM: Histopathologic characterization of
radioactive iodine-refractory fluorodeoxyglucose-positron emission
tomography-positive thyroid carcinoma. Cancer. 113:48–56. 2008.
View Article : Google Scholar : PubMed/NCBI
|
